DSG2 is overexpressed and a predictor of poor prognosis in multiple types of cancer, including skin [5,6], non-small cell lung cancer [7], lung adenocarcinoma [8,9], hepatocellular carcinoma [10], ovarian cancer [11], and gastric cancer [12], indicating that tumors take advantage of DSG2 overexpression as a means of forming tight physical barriers and contributing to resistance against therapeutics [13,14]. This evidence concerns the gene DSG2 and cancer.